Citations

Mayo Clinic

Showing 10 of 108599 citations.

Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, with HER2 FISH Correlation: A Cohort of 112 Patients
Ardor, Gokce Deniz , Hanna, Helena, Ibanoglu, Onur, Lochala, Abigail, Nassar, Aziza , Komforti, Miglena K. , Nassar, Aziza

The Breast Journal | August 25, 2023 | Volume: 2023 | Issue: No issue available | Pages: 1-7

10.1155/2023/9725647 | PMID 37664543 Get It

Introduction. Recent trials demonstrated clinically significant benefits in HER2-nonamplified breast cancer with HER2-low expression using novel anti-HER2 antibody-drug conjugates. Thus, HER2-low breast cancer was proposed as a separate diagnostic entity. Herein, we reclassify HER2-negative cancers according to the new HER2-low category using a modified system and further investigate HER2-very-low expression. Methods. 114 HER2 immunohistochemistry (IHC)-negative invasive breast tumors were identified from the pathology database of Mayo Clinic, Jacksonville, FL, between January 2019 and August 2022. Two blinded breast pathologists (BP) independently rescored HER2 IHC slides at 200x and 400x magnification. Discordant cases between the two BPs were rescored together. The most recent 2018 ASCO/CAP HER2 scoring criteria were used. HER2 (0) was subdivided into HER2 (absent) and HER2 (very low). HER2 FISH testing was performed in all cases. Results. The cohort comprised of 38 (33.3%) HER2 (0) and 76 (66.7%) HER2 (1+) tumors. The first round of rescoring at 200x and 400x magnification resulted in 17 (14.9%) HER2 (absent), 31 (27.2%) HER2 (very low), and 64 (56.2%) HER2 (1+) and 2 (1.8%) HER2 (2+) tumors by BP1 and 20 (17.5%) HER2 (absent), 33 (28.9%) HER2 (very low), and 61 (53.5%) HER2 (1+) tumors by BP2. The combined final rescoring by BP1 and BP2 was as follows: 15 (13.2%) HER2 (absent), 35 (30.7%) HER2 (very low), 63 (55.3%) HER2 (1+), and 1 (0.9%) HER2 (2+) cases. A comparison of the first round of rescoring between two BPs showed substantial agreement with Cohen’s kappa value of 0.67. Both comparisons of first rescoring by BP1 and by BP2 to combined final rescoring showed almost perfect agreement with Cohen’s kappa value of 0.83.Follow-up FISH studies showed one amplified tumor. Conclusion. Our data support the need for finer granularity, classification, and understanding of HER2-low breast cancers. We also show that reproducibility between trained BP can be obtained, albeit with scoring at high power and low threshold for showing challenging interpretations.
Impact of Biologic Augmentation on Revision Surgery Rates After Meniscus Repair: A Matched-Cohort Analysis of 3420 Patients
Dancy, Malik E. , Marigi, Erick M. , Krych, Aaron J. , Werner, Brian C. , Camp, Christopher L.

Orthopaedic Journal of Sports Medicine | August 25, 2023 | Volume: 11 | Issue: 8 | Pages: No page available

10.1177/23259671231186990 | PMID 37655247 Get It

Background: Platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC) have gained popularity in recent years as biologic approaches to potentially augment healing after meniscus repair. There have been few studies comparing outcomes in patients undergoing meniscus repair with versus without biologic augmentation and, furthermore, little clarity on the role of biologic augmentation for meniscus repairs performed with concomitant anterior cruciate ligament reconstruction (ACLR). Purpose: To determine the association of BMAC or PRP augmentation with revision surgery after both isolated meniscus repair and meniscus repair performed concomitantly with ACLR. Study Design: Cohort study; Level of evidence, 3. Methods: The PearlDiver Mariner dataset was queried to identify all patients who underwent primary meniscus repair, both with and without concomitant ACLR, and who received ipsilateral BMAC or PRP at the time of surgery. Patients who underwent similar surgery but without BMAC or PRP augmentation were then identified and matched in a 5:1 ratio according to age, sex, body mass index, and various comorbidities to 3 separate BMAC/PRP augmentation groups: overall cohort (with and without ACLR), repair with concomitant ACLR, and isolated repair. The primary outcome was revision meniscus surgery (meniscectomy or revision meniscus repair). Results: Overall, 3420 patients (570 with BMAC/PRP augmentation; 2850 matched controls without augmentation) were included. There were no significant differences in the reported demographics or comorbidities between any of the BMAC/PRP groups and their respective matched controls ( P > .05 for all comparisons). There was no difference in revision rate between BMAC/PRP-augmented isolated meniscus repairs and matched controls ( P = .235). Patients who underwent BMAC/PRP-augmented meniscus repair with concomitant ACLR experienced a significantly lower incidence of revision surgery compared with matched controls without BMAC/PRP augmentation (5.2% vs 7.9% respectively; odds ratio, 0.41; 95% CI, 0.27-0.63; P < .001), but the number of revisions was relatively small. Conclusion: There was no association between BMAC or PRP augmentation and the incidence of revision surgery after isolated primary meniscus repair. There was a statistically significant decrease in the rate of revision meniscus surgery when BMAC or PRP was used to augment meniscus repairs in the setting of concurrent ACLR; however, the overall revision rates were small.
Deep-RSI: Deep learning for Radiographs Source Identification
Mohammadi, Farid Ghareh , Sebro, Ronnie

2022 International Conference on Computational Science and Computational Intelligence (CSCI) | August 25, 2023 | Volume: No volume available | Issue: No issue available | Pages: 1491-1496

10.1109/csci58124.2022.00264 Get It

Including the method of detection for breast cancer in the Surveillance, Epidemiology, and End Results database is long overdue
Kopans, Daniel B. , Sharpe, Richard E. , Eby, Peter R.

Journal of Medical Screening | August 25, 2023 | Volume: 31 | Issue: 1 | Pages: 1-2

10.1177/09691413231197131 | PMID 37624726 Get It

Debates about breast cancer screening have continued in part because the Surveillance, Epidemiology, and End Results database, which began in 1974, has never included the method of detection so that it has been impossible to determine the role that early detection has played in the major decline in deaths from breast cancer that we have seen in the US since 1990. Method of detection should be added to the Surveillance, Epidemiology, and End Results database as soon as possible.
Life‐Threatening Subglottic Thrombus Formation after Administration of Nebulized Tranexamic Acid
Awadallah, Andrew S. , Armstrong, Michael , Aden, Aisha A. , Weidermann, Joshua, Bayan, Semirra L. , Ekbom, Dale C. , Awadallah, Andrew , Aden, Aisha , Armstrong, Michael F , Bayan, Semirra

The Laryngoscope | August 25, 2023 | Volume: 134 | Issue: 3 | Pages: 1356-1358

10.1002/lary.30973 | PMID 37622726 Get It

From gene-discovery to gene-tailored clinical management: 25 years of research in channelopathies and cardiomyopathies
Crotti, Lia , Brugada, Pedro , Calkins, Hugh , Chevalier, Philippe , Conte, Giulio , Finocchiaro, Gherardo , Postema, Pieter G. , Probst, Vincent , Schwartz, Peter J. , Behr, Elijah R. , Schwartz, Peter J. , Crotti, Lia , Behr, Elijah Raphael , Probst, Vincent , Conte, Giulio , Postema, Pieter G

Europace | August 25, 2023 | Volume: 25 | Issue: 8 | Pages: No page available

10.1093/europace/euad180 | PMID 37622577 Get It

Abstract In the early nineties, few years before the birth of Europace, the clinical and scientific world of familial arrhythmogenic conditions was revolutionized by the identification of the first disease-causing genes. The explosion of genetic studies over a 15-year period led to the discovery of major disease-causing genes in practically all channelopathies and cardiomyopathies, bringing insight into the pathophysiological mechanisms of these conditions. The birth of next generation sequencing allowed a further step forward and other significant genes, as CALM1–3 in channelopathies and FLN C and TTN in cardiomyopathies were identified. Genotype–phenotype studies allowed the implementation of the genetic results in diagnosis, risk stratification, and therapeutic management with a different level of evidence in different arrhythmogenic conditions. The influence of common genetic variants, i.e. SNPs, on disease manifestation was proved in mid-twenties, and in the last 10 years with the advent of genome-wide association studies performed in familial arrhythmogenic diseases, the concept of polygenic risk score has been consolidated. Now, we are at the start of another amazing phase, i.e. the initiation of first gene therapy clinical trials.
Characterizing Performance Gaps of a Code-Based Dementia Algorithm in a Population-Based Cohort of Cognitive Aging
Vassilaki, Maria , Christenson, Luke R., Garg, Muskan , Petersen, Ronald C. , Sohn, Sunghwan , St Sauver, Jennifer, Fu, Sunyang , Sauver, Jennifer L. St.

Journal of Alzheimer’s Disease | August 25, 2023 | Volume: 95 | Issue: 3 | Pages: 931-940

10.3233/jad-230344 | PMID 37638438 Get It

Background: Multiple algorithms with variable performance have been developed to identify dementia using combinations of billing codes and medication data that are widely available from electronic health records (EHR). If the characteristics of misclassified patients are clearly identified, modifying existing algorithms to improve performance may be possible. Objective: To examine the performance of a code-based algorithm to identify dementia cases in the population-based Mayo Clinic Study of Aging (MCSA) where dementia diagnosis (i.e., reference standard) is actively assessed through routine follow-up and describe the characteristics of persons incorrectly categorized. Methods: There were 5,316 participants (age at baseline (mean (SD)): 73.3 (9.68) years; 50.7% male) without dementia at baseline and available EHR data. ICD-9/10 codes and prescription medications for dementia were extracted between baseline and one year after an MCSA dementia diagnosis or last follow-up. Fisher’s exact or Kruskal-Wallis tests were used to compare characteristics between groups. Results: Algorithm sensitivity and specificity were 0.70 (95% CI: 0.67, 0.74) and 0.95 (95% CI: 0.95, 0.96). False positives (i.e., participants falsely diagnosed with dementia by the algorithm) were older, with higher Charlson comorbidity index, more likely to have mild cognitive impairment (MCI), and longer follow-up (versus true negatives). False negatives (versus true positives) were older, more likely to have MCI, or have more functional limitations. Conclusions: We observed a moderate-high performance of the code-based diagnosis method against the population-based MCSA reference standard dementia diagnosis. Older participants and those with MCI at baseline were more likely to be misclassified.
Three-dimensional mitochondria reconstructions of murine cardiac muscle changes in size across aging
Vue, Zer , Neikirk, Kit , Vang, Larry , Christensen, Trace , Shao, Jianqiang, Lam, Jacob , Marshall, Andrea G. , Crabtree, Amber , Anudokem, Josephs , Kirk, Benjamin , Bacevac, Serif, Barongan, Taylor , Shao, Bryanna, Stephens, Dominique C., Kabugi, Kinuthia, Koh, Ho‐Jin , Koh, Alice, Evans, Chantell S. , Reddy, Anilkumar K. , Actkins, Ky’Era V. , Zaganjor, Elma , Daneshgar, Nastaran , Murray, Sandra , Mobley, Bret C. , Gaddy, Jennifer A. , Riggs, Blake , McReynolds, Melanie R. , Gómez, José A. , Phillips, Mark , Exil, Vernat , Hinton, Antentor , Lam, Jacob , Beasley, Heather K , Marshall, Andrea G , Crabtree, Amber , Anudokem, Josephs , Barongan, Taylor , Evans, Chantell S , Daneshgar, Nastaran , Murray, Sandra A , Wanjalla, Celestine , Kirabo, Annet , Gomez, Jose A , Hinton, Antentor , Exil, Vernat , Garza-López, Edgar , Beasley, Heather K. , Rodríguez, Blanca , Kirk, Benjamin, Taylor, Brittany , Miller‐Fleming, Tyne W. , Damo, Steven M. , Wanjalla, Celestine N. , Dai, Dao‐Fu

American Journal of Physiology-Heart and Circulatory Physiology | August 25, 2023 | Volume: 325 | Issue: 5 | Pages: H965-H982

10.1152/ajpheart.00202.2023 | PMID 37624101 Get It

This article shows how mitochondria in murine cardiac changes, importantly elucidating age-related changes. It also is the first to show that the MICOS complex may play a role in outer membrane mitochondrial structure.